You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.
It is possible that some of the products on the other site not be licensed for sale in Canada.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
By choosing to accept, you acknowledge that you are a Certified Healthcare Professional.
Atrial Fibrillation (AF) can spontaneously organize to slower and/or more organized atrial rhythms. The Reactive ATP™ (rATP) algorithm delivers atrial antitachycardia pacing (ATP) to terminate an ongoing atrial fibrillation (AF) episode after a programmed interval or when the rhythm organizes and/or slows.
aATP† + atrial intervention + MVP arm compared to control arm
The Reactive ATP algorithm studied in the MINERVA trial is available in our dual chamber pacemakers and ICDs, as well as our CRT-Ds and CRT-Ps.
Reactive ATP was referred to as 'aATP' in the MINERVA trial
Model components included group, age, sex, baseline AF, and device type. Frailty model results were consistent with those from Cox proportional hazard models (P< 0.0001 for all).
Follow these steps to turn Reactive ATP on in pacemaker, implantable cardioverter defibrillator (ICD), and cardiac resynchronization therapy (CRT) devices after lead maturation.
Boriani G, Manolis AS, Tukkie R, et al. Effects of enhanced pacing modalities on health care resource utilization and costs in bradycardia patients: An analysis of the randomized MINERVA trial. Heart Rhythm. June 2015;12(6):1192-1200.
Hudnall H. Reactive Atrial-based Antitachycardia Pacing Therapy to Slow Progression of Atrial Fibrillation. August 2017, Medtronic data on file. Manuscript in preparation.